Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

Chronic hepatitis C virus (HCV) infection affects an estimated 71.1 million patients worldwide in 2015 and is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC).[1] Among patients who have undergone treatment with curative intent for HCC, early hepatic decompensation and HCC recurrence were the major drivers of mortality.[2] In recent studies of chronic hepatitis B-related HCC, antiviral therapy was shown to significantly reduce overall long-term mortality even in patients with very advanced HCC or decompensated cirrhosis, including those who were only receiving palliative treatment for HCC.

Source: Journal of Hepatology - May 12, 2019 Category: Gastroenterology Authors: Fanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, Eiichi Ogawa, Masaru Enomoto, Dong Hyun Lee, Etsuko Iio, John Lubel, Wenjun Wang, Bin Wei, Tatsuya Ide, Carmen Monica Preda, Fabio Conti, Tatsuya Minami, Rob Bielen, Hitomi Sezaki, Michele Barone, Philippe Kolly, Po Source Type: research